

The Interface of Medical and Psychiatric Disorders: Focus on Cancer and Heart Disease

presented by

Charles Nemeroff, MD, PhD

Charles Nemeroff is chair and professor with the Department of Psychiatry and Behavioral Sciences. He also directs the Institute for Early Life Adversity Research within the Department of Psychiatry and Behavioral Sciences as part of the Mulva Clinic for the Neurosciences. Prior to joining Dell Med, Nemeroff served as chair of the Department of Psychiatry and Behavioral Sciences and clinical director of the Center on Aging at the University of Miami- Miller School of Medicine in Miami, Florida. He received his medical degree and doctorate degrees in neurobiology from the University of North Carolina School of Medicine. After psychiatry residency training at UNC and Duke University, he held faculty positions at Duke University Medical Center and at Emory University School of Medicine before relocating to the University of Miami in 2009.

Thursday, September 16, 2021 @ 12:00pm

Online via Zoom

<https://us02web.zoom.us/j/83274750174?pwd=N2M5SG1QOUlOdHlaYXU1SmxGdHBYUT09>

Meeting ID: 832 7475 0174

Passcode: bJM2Wf

Learning Objectives: *As a result of participating in this Live Activity, participants should be able to:*

- 1 Review the biology of mood disorders and how they increase risk for cancer and heart disease
- 2 Discuss the poor medical prognosis for patients with mood disorders
- 3 Describe available data on treatment of patients with comorbid medical disorders

Accreditation Statement: In support of improving patient care, Hartford HealthCare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Credit Designation Statement: Hartford Healthcare designates this Live Activity for 1.25 *AMA PRA Category 1 Credit(s)*[™]. Physicians should only claim credit commensurate with their participation.

Financial Disclosures:

Name of individual	Individual's role in activity	Name of commercial interest/Nature of relationship
Erica Moura, LCSW, MBA	Activity Coordinator	Nothing to disclose - 08/30/2021

Charles Nemeroff, MD, PhD	Faculty	<p>Contracted Research-National Institutes of Health Consulting Fee- ANeuroTech Consulting Fee-Signant Health Consulting Fee-Magstim Consulting Fee-Navitor Consulting Fee-Intra-Cellular Therapies, Inc. Consulting Fee-EMA Wellness Consulting Fee-Acadia Pharmaceuticals Consulting Fee-Sage Therapeutics Consulting Fee-BioXcel Therapeutics Consulting Fee-Silo Pharma Consulting Fee-XW Pharma Consulting Fee-Neuritek Consulting Fee-Engrail Therapeutics Consulting Fee-Corcept Consulting Fee-SK Life Science Receipt of Intellectual Property Rights/Patent Holder-Method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay (US 7,148,027B2) Receipt of Intellectual Property Rights/Patent Holder-Method and devices for transdermal delivery of lithium (US 6,375,990B1) Stockholder-Xhale Stockholder-Seattle Genetics Stockholder-Antares Stockholder-BI Gen Holdings Stockholder-Corcept Stockholder-EMA Wellness Stockholder-TRUUST Neuroimaging Board of Directors-Gratitude America Board of Directors-ADAA Board of Directors-Xhale Smart, Inc Scientific Advisory Boards-ANeuroTech, Brain and Behavior Research Foundation (BBRF), Anxiety and Depression Association of America (ADAA), Skyland Trail, Signant Health, Laureate Institute for Brain Research (LIBR), Inc., Magnolia CNS, Heading Health, TRUUST Neuroimaging - 08/19/2021</p>

